SM
MRNA icon

SG3 Management’s Moderna MRNA Stock Holding History

SG3 Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,400
Closed -$11.5M – 1235
2021
Q4 		$11.5M Sell
45,400
-10,000
-18% -$2.92M 0.23% 73
2021
Q3 		$21.3M Sell
55,400
-10,000
-15% -$3.69M 0.65% 20
2021
Q2 		$15.4M Sell
65,400
-22,600
-26% -$4.04M 0.55% 32
2021
Q1 		$11.5M Sell
88,000
-151,000
-63% -$21.9M 0.29% 75
2020
Q4 		$25M Buy
239,000
+209,000
+697% +$21.1M 0.48% 35
2020
Q3 		$2.12M Sell
30,000
-15,000
-33% -$1.05M 0.08% 259
2020
Q2 		$2.89M Buy
45,000
+20,000
+80% +$1.1M 0.2% 134
2020
Q1 		$749K Buy
+25,000
New +$575K 0.1% 128

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SG3 Management's MRNA Position: Q1 2022 in Review

SG3 Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 19,000 shares — an estimated $3.2M sold.

SG3 Management first reported a position in MRNA in Q2 2020 and held it in 4 quarters. The position peaked at $20.2M in Q3 2021. 1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • SG3 Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 19,000 Moderna shares in Q1 2022, an estimated $3.2M.
  • SG3 Management first reported a position in Moderna in Q2 2020 and held it in 4 quarters.
  • SG3 Management's Moderna position peaked at $20.2M in Q3 2021.
  • 1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.